in

EQRX wants to make high-end medicines less costly

A Boston-based biotech startup thinks it has found a lucrative third way between high-margin branded drugs and high-volume generics

Source: Business - economist.com

Can the World Economic Forum keep its mojo?

Big Oil has a do-or-die decade ahead because of climate change